tiprankstipranks

Kenneth Glass Insider Profile

4 Followers
Kenneth Glass, Director at Oncternal Therapeutics, holds 204.82K shares in Oncternal Therapeutics (Ticker: ONCT), holds 499.58K shares in First Horizon (Ticker: FHN), holds 0.00 shares in FedEx (Ticker: FDX). Most recently, Kenneth Glass Bought ― shares of Oncternal Therapeutics on Mar 02, 2016 for an estimated value of 26.40K.
tipranks
Kenneth Glass

Kenneth Glass
Oncternal Therapeutics (ONCT)
Director

Ranked #81,752 out of 98,909 Corporate Insiders

Profitable Transactions

22%
2 out of 9 Profitable Transactions

Average Return

-16.90%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$10M
81.75%
18.25%
0.00%
A breakdown of Kenneth Glass's holdings

Insider Roles

First Horizon
(FHN)
Director
Oncternal Therapeutics
(ONCT)
Director
FedEx
(FDX)
Director
Roles that Kenneth Glass holds in companies

Most Profitable Insider Trade

Stock:
Oncternal Therapeutics
(ONCT)
Rating:Informative Buy
Date:Apr 23, 2015 - Apr 23, 2016
Return:+12.60%
The most profitable trade made by Kenneth Glass

Kenneth Glass's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Oncternal Therapeutics
Mar 02, 2016
Director
Informative Buy
26.40K
$1.76M
First Horizon
Director
$7.89M
FedEx
Director
$0.00
List of latest transactions for each holding click on a transaction to see Kenneth Glass's performance on stock

Kenneth Glass insider profile FAQ

What is the percentage of profitable transactions made by Kenneth Glass?
The percentage of profitable transactions made by Kenneth Glass is 22%.
    What is the average return per transaction made by Kenneth Glass?
    The average return per transaction made by Kenneth Glass is -16.90%.
      What stocks does Kenneth Glass hold?
      Kenneth Glass holds: ONCT, FHN, FDX stocks.
        What was Kenneth Glass’s latest transaction?
        Kenneth Glass latest transaction was an Informative Buy of $26.40K.
          What was Kenneth Glass's most profitable transaction?
          Kenneth Glass’s most profitable transaction was an Informative Buy of ONCT stock on April 23, 2015. The return on the trade was 12.60%.
            What is Kenneth Glass's role in Oncternal Therapeutics?
            Kenneth Glass's role in Oncternal Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.